PATENT CLAIM ANALYSIS

Application Number: 16014231
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "259300"]

Abstract:
Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Claim (Index 12):
The compound of  claim 1 , or a stereoisomer or pharmaceutically acceptable salt thereof, wherein the ring heteroatoms of the 3-11 membered saturated or partially saturated heterocyclic group of R 5  are selected from nitrogen and oxygen.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 94.0
- Lexical Diversity: 1.21739
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15905524', '15305390', '15247429', '15822493', '15305372']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8218675304414997
- 35 USC 102 Novelty (BERT): 0.5484769860234358
- Combined Prediction Score: 0.7945284759996935
- Mean Citation Score: 404.523194
- Max Citation Score: 418.23807
- Similarity Product: 305.27570766978266

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test